Chimeric Antigen Receptor T Cell Therapy During the COVID-19 Pandemic.
Biol Blood Marrow Transplant
; 26(7): 1239-1246, 2020 07.
Article
in English
| MEDLINE | ID: covidwho-100212
ABSTRACT
The SARS-CoV-2 coronavirus (COVID-19) pandemic has significantly impacted the delivery of cellular therapeutics, including chimeric antigen receptor (CAR) T cells. This impact has extended beyond patient care to include logistics, administration, and distribution of increasingly limited health care resources. Based on the collective experience of the CAR T-cell Consortium investigators, we review and address several questions and concerns regarding cellular therapy administration in the setting of COVID-19 and make general recommendations to address these issues. Specifically, we address (1) necessary resources for safe administration of cell therapies; (2) determinants of cell therapy utilization; (3) selection among patients with B cell non-Hodgkin lymphomas and B cell acute lymphoblastic leukemia; (4) supportive measures during cell therapy administration; (5) use and prioritization of tocilizumab; and (6) collaborative care with referring physicians. These recommendations were carefully formulated with the understanding that resource allocation is of the utmost importance, and that the decision to proceed with CAR T cell therapy will require extensive discussion of potential risks and benefits. Although these recommendations are fluid, at this time it is our opinion that the COVID-19 pandemic should not serve as reason to defer CAR T cell therapy for patients truly in need of a potentially curative therapy.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
T-Lymphocytes
/
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
/
Immunotherapy, Adoptive
/
Lymphoma, B-Cell
/
Coronavirus Infections
/
Pandemics
Type of study:
Observational study
/
Prognostic study
/
Qualitative research
Limits:
Humans
Country/Region as subject:
North America
Language:
English
Journal:
Biol Blood Marrow Transplant
Journal subject:
Hematology
/
Transplantation
Year:
2020
Document Type:
Article
Affiliation country:
J.bbmt.2020.04.008
Similar
MEDLINE
...
LILACS
LIS